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To the Editor

E

mberger syndrome is an autosomal dominantly
inherited multisystemic disorder characterized
by primary lower limb lymphedema associated with
predisposition to myelodysplasia and acute myeloid
leukemia [1]. It was ﬁrst described in 1979 by
Emberger et al. [2] who reported a two generational
family with four individuals affected with severe
postlingual congenital deafness, lymphedema, and
hematological malignancies.
In 2011, Ostergaard et al. [1] identiﬁed heterozygous (haploinsufﬁciency) GATA2 germline mutations in patients with Emberger syndrome [3].
GATA2 deﬁciency is now recognized as a protean
disorder of hematopoiesis, lymphatics, skin, and
immunity [4]. GATA2, which encodes three transcripts, is one of six ‘WGATAR’ DNA motif binding
transcription factors that regulate gene expression
and also interact with other transcription factors via
two zinc ﬁnger domains where most described
mutations cluster. In primitive hematopoietic cells,
GATA2 complexes with six other factors (TAL1,
LYL1, LMO2, ERG, FLI1, and RUNXI) as a core
heptad regulatory unit within a much larger complex [5].

Here, we report a family of three siblings who
presented with various features of GATA2 deﬁciency
syndrome despite the lack of symptoms in their
consanguineous 67-year-old father and 54-year-old
mother. This study was approved by the King Faisal
Specialist Hospital and Research Center Institutional
Review Board (RAC #2060021). The proband (Patient
1) was a 20-year-old female who presented with biopsy-proven bilateral lower limb panniculitis, which
was partially responsive to oral prednisone. She had
marked bilateral lower limb lymphedema. Also, she
complained of diffuse joint pain without other signs
of inﬂammation. Laboratory studies showed persistent normocytic normochromic anemia with anisopoikilocytosis (hemoglobin 92 g/L), monocytopenia
(0.07  109/L), T cell (0.69  109/L) and B cell lymphopenia (0.007  109/L), and transient hypereosinophilia (2.2  109/L). She also had hyperimmunoglobulin E (hyper-IgE) (6,620 KU/L) and
normal IgA, IgG, and IgM levels. Extensive autoimmune studies showed only elevated antinuclear
antibody (1:160, speckled), anticardiolipin IgG (18.1
GPL U/ml), antiphosphatidylserine IgG and IgM
antibodies (17.8 GPS and 32.8 MPS U/mL, respectively), and raised soluble CD25 level (2415 pg/mL).
Major histocompatibility class (MHC) II genotyping
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revealed HLA-DRB1*07:01*07:01, DQB1*02:02;*02:03
alleles. Blood chromosome breakage analysis with
diepoxybutane was normal, while bone marrow examination was not done. Total body positron emission tomography-computed tomography scan
showed widening of the auditory canals, otosclerosis, and massive lower limb edema with fat
stranding and fascial circumferential soft tissue
density localized in both calves and feet. Full
GATA2 gene mutation analysis of peripheral blood
genomic DNA using next generation sequencing
revealed a novel and likely pathogenic heterozygous
missense mutation (NM_001145661.1:c.1121G > A;
p.Gly374Asp), located on chr3(GRCh37):g128200684.
The mutation resides in exon 5 within the second
zinc-ﬁnger domain of GATA2. This novel mutation
is absent from the public gnomAD (www.gnomad.broadinstitute.org) as well as our internal Saudi
Genome Program (www.saudigenomeprogram.org/)
databases. The proband’s 32-year-old sister (Patient
2) had hypocellular myelodysplastic bone marrow
with subsequent transformation to acute myeloblastic leukemia. Lung biopsy showed lymphocytic
interstitial pneumonia which appeared as cystic lung
disease on chest computed tomography. Pulmonary
function testing showed obstructive and restrictive
features. She also had monocytopenia, B and T cell
lymphopenia, with intermittently positive rheumatoid factor, SS-B (La), anticardiolipin IgG/IgM, antib2-glycoprotein I IgM, and lupus anticoagulant.
MHCII genotyping showed HLA-DRB1*03:01;03:01,
DQA1*05:01;05:10, and DQB1*02:01;02:01. Bone
marrow karyotype showed monosomy 7 and trisomy
8. She died shortly after receiving induction
chemotherapy. Work up of the 20-year-old asymptomatic brother (Patient 3) who was a potential bone
marrow donor showed leukopenia (lymphopenia,
monocytopenia), thrombocytopenia, and moderately
hypocellular nondysplastic bone marrow with some
megaloblastoid changes. MHC genotyping showed
HLA-A*03:01, B*50:01, C*06:02:04, DRB1*03:01;03:01,
DQB1*02:01;02:01. Two other siblings (25-year-old
sister and 27-year-old brother) appeared to be
healthy. The parents of these ﬁve siblings denied any
signiﬁcant health problems. However, they have not
had direct analysis of this novel GATA2 mutation.
In this new family with the GATA2 deﬁciency
syndrome, we observed the full spectrum of the
clinical features of this syndrome which involved
hematopoiesis, skin, vasculature/lymphatics, and
immunity. We are particularly intrigued by the
autoimmunity, hyper-IgE level as well as the lack of
symptoms (non-penetrance so far) in either parent,
although one of them is an obligate carrier. Autoimmune conditions like autoimmune hepatitis,

autoimmune cytopenias, and arthritis have been
reported in patients with GATA 2 deﬁciency [6,7].
One possible mechanism is the expansion of a small
subset of CD38 CD21 B cells associated with
autoimmunity [8].
While a few large series of patients with GATA2
deﬁciency have been published, to our knowledge,
hyper-IgE has not been recognized as a component of
this syndrome. GATA2 induced by STAT5 is also
critical for mast cell and basophil differentiation
which in addition to monocytes and dendritic cells
constitutively express the high-afﬁnity IgE receptor
FceR1A. Endocytosis of this receptor contributes to
normal serum IgE clearance [9,10]. Consequently, the
monocytopenia and dendritic cell deﬁciency found in
GATA2 deﬁciency may impair the kinetics of serum
IgE clearance. Although the proband had several
drug allergies, she lacked the clinical features of the
autosomal dominant (Job syndrome, STAT3) or
autosomal recessive (DOCK8/PGM3/IL6ST/ZNF341)
hyper-IgE syndrome. The mechanism which underlies high IgE levels in these disorders remains
poorly understood, but may involve an increase in
Th2 cells. In some patients, T cells displayed defects in
both nuclear factor-kappa B and mammalian target of
rapamycin complex 1 activation, which might underlie their abnormal IgE production [11,12].
Despite their lymphopenia, the three affected
siblings have not had any signiﬁcant history of severe viral, fungal, or nontuberculous mycobacterial
infections. The presence of low levels of likely
nonpathogenic antinuclear and antiphospholipid
antibodies could relate to the HLA-DQB1*02:02 and
02:03 alleles, which in conjunction with DRB1*03:01,
are associated with several autoimmune disorders,
like in their sister with triple-positive antiphospholipid antibody syndrome who carried both
risk alleles DRB1*03:01 and DQB1*02:01 [13,14].
Finally, due to the complexity of GATA2 deﬁciency, affected patients and their families need
comprehensive multidisciplinary clinical care. Also,
additional multi-omics investigations may help unravel its complex pathogenesis.
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